Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
Washington University School of Medicine
Essen Biotech
Alliance for Clinical Trials in Oncology
University of Nebraska
National Cancer Institute (NCI)
Adela, Inc
M.D. Anderson Cancer Center
Eli Lilly and Company
Var2 Pharmaceuticals
University Health Network, Toronto
M.D. Anderson Cancer Center
British Columbia Cancer Agency
Washington University School of Medicine
Travera Inc
Guangzhou FineImmune Biotechnology Co., LTD.
Washington University School of Medicine
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Turning Point Therapeutics, Inc.
Institut Bergonié
University of California, Irvine
Cancer Research UK
Tempus AI
National Institutes of Health Clinical Center (CC)
Elevation Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Rutgers, The State University of New Jersey
Actuate Therapeutics Inc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
National Cancer Institute (NCI)
Zhejiang Provincial People's Hospital
Washington University School of Medicine
Second Affiliated Hospital of Guangzhou Medical University
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
RefleXion Medical
pharmaand GmbH
M.D. Anderson Cancer Center